Advances in Cancer Research最新文献_第4页

The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma. galectin-3 在黑色素瘤进展过程中的多向作用：解开谜团

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2022-08-08 DOI: 10.1016/bs.acr.2022.06.001

Norhan B B Mohammed, Aristotelis Antonopoulos, Anne Dell, Stuart M Haslam, Charles J Dimitroff

引用次数: 0

Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions. 肿瘤异质性：压力条件下 PDAC 进展和耐药性的致癌驱动因素。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-04-21 DOI: 10.1016/bs.acr.2023.02.005

António M Palma, Vignesh Vudatha, Maria Leonor Peixoto, Esha Madan

{"title":"Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions.","authors":"António M Palma, Vignesh Vudatha, Maria Leonor Peixoto, Esha Madan","doi":"10.1016/bs.acr.2023.02.005","DOIUrl":"10.1016/bs.acr.2023.02.005","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging disease usually diagnosed at advanced or metastasized stage. By this year end, there are an expected increase in 62,210 new cases and 49,830 deaths in the United States, with 90% corresponding to PDAC subtype alone. Despite advances in cancer therapy, one of the major challenges combating PDAC remains tumor heterogeneity between PDAC patients and within the primary and metastatic lesions of the same patient. This review describes the PDAC subtypes based on the genomic, transcriptional, epigenetic, and metabolic signatures observed among patients and within individual tumors. Recent studies in tumor biology suggest PDAC heterogeneity as a major driver of disease progression under conditions of stress including hypoxia and nutrient deprivation, leading to metabolic reprogramming. We therefore advance our understanding in identifying the underlying mechanisms that interfere with the crosstalk between the extracellular matrix components and tumor cells that define the mechanics of tumor growth and metastasis. The bilateral interaction between the heterogeneous tumor microenvironment and PDAC cells serves as another important contributor that characterizes the tumor-promoting or tumor-suppressing phenotypes providing an opportunity for an effective treatment regime. Furthermore, we highlight the dynamic reciprocating interplay between the stromal and immune cells that impact immune surveillance or immune evasion response and contribute towards a complex process of tumorigenesis. In summary, the review encapsulates the existing knowledge of the currently applied treatments for PDAC with emphasis on tumor heterogeneity, manifesting at multiple levels, impacting disease progression and therapy resistance under stress.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"159 ","pages":"203-249"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9653442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The epigenome and the many facets of cancer drug tolerance. 表观基因组和癌症药物耐受性的许多方面。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.1016/bs.acr.2022.12.002

Paul C Moore, Kurt W Henderson, Marie Classon

{"title":"The epigenome and the many facets of cancer drug tolerance.","authors":"Paul C Moore, Kurt W Henderson, Marie Classon","doi":"10.1016/bs.acr.2022.12.002","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.12.002","url":null,"abstract":"The use of chemotherapeutic agents and the development of new cancer therapies over the past few decades has consequently led to the emergence of myriad therapeutic resistance mechanisms. Once thought to be explicitly driven by genetics, the coupling of reversible sensitivity and absence of pre-existing mutations in some tumors opened the way for discovery of drug-tolerant persisters (DTPs): slow-cycling subpopulations of tumor cells that exhibit reversible sensitivity to therapy. These cells confer multi-drug tolerance, to targeted and chemotherapies alike, until the residual disease can establish a stable, drug-resistant state. The DTP state can exploit a multitude of distinct, yet interlaced, mechanisms to survive otherwise lethal drug exposures. Here, we categorize these multi-faceted defense mechanisms into unique Hallmarks of Cancer Drug Tolerance. At the highest level, these are comprised of heterogeneity, signaling plasticity, differentiation, proliferation/metabolism, stress management, genomic integrity, crosstalk with the tumor microenvironment, immune escape, and epigenetic regulatory mechanisms. Of these, epigenetics was both one of the first proposed means of non-genetic resistance and one of the first discovered. As we describe in this review, epigenetic regulatory factors are involved in most facets of DTP biology, positioning this hallmark as an overarching mediator of drug tolerance and a potential avenue to novel therapies.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"158 ","pages":"1-39"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9335657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. 解密胰腺癌上皮细胞向间质转化的过程。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-03-23 DOI: 10.1016/bs.acr.2023.02.008

Creighton Friend, Parash Parajuli, Mohammed S Razzaque, Azeddine Atfi

引用次数: 0

Measuring the multifaceted roles of mucin-domain glycoproteins in cancer. 测量粘蛋白结构域糖蛋白在癌症中的多方面作用。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2022-10-08 DOI: 10.1016/bs.acr.2022.09.001

Nicholas M Riley, Ru M Wen, Carolyn R Bertozzi, James D Brooks, Sharon J Pitteri

引用次数: 0

Clinical evidence of neoadjuvant immunotherapy for resectable locally advanced esophageal carcinoma: A systematic review 新辅助免疫治疗可切除局部晚期食管癌的临床证据:一项系统综述

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.53388/2023623013

Zikun Wu, Chong Xiao, Xue-Ke Li, Feng-Ming You

{"title":"Clinical evidence of neoadjuvant immunotherapy for resectable locally advanced esophageal carcinoma: A systematic review","authors":"Zikun Wu, Chong Xiao, Xue-Ke Li, Feng-Ming You","doi":"10.53388/2023623013","DOIUrl":"https://doi.org/10.53388/2023623013","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) as the neoadjuvant therapy for resectable locally advanced esophageal carcinoma (rlaEC) remains challenging given the poor reports of efficacy and safety. This study aimed to summarize reliable evidence for the preoperative neoadjuvant immunotherapy of rlaEC by analyzing all the published clinical trials on the ICIs as the neoadjuvant therapy for rlaEC. Methods: PubMed, Cochrane Library, Embase and ClinicalTrials.gov were searched from inception until June 1st, 2023, for available reports to perform a meta-analysis. The primary endpoints were R0 resection, objective response rate (ORR), pathological complete response (pCR) and major pathological response (MPR), as well as treatment-related adverse events (AEs) and postoperative complications. The Stata 14.0 software was employed to estimate pooled effect size. Results: A total of 18 single-arm clinical trials involving 625 patients met the inclusion criteria. Meta-analysis showed that, among these patients with rlaEC, the pooled R0 resection rate was 97.0% (95% CI: 94.0% – 99.0%), the pooled ORR was 70.0% (95% CI: 64.0% – 76.0%), the pooled pCR and MPR rate were 34.0% (95 % CI: 29.0% – 39.0%) and 56.0% (95% CI: 47.0% – 65.0%) respectively. The incidence of main treatment-related AEs and postoperative complications was about 6% – 45% and 8% – 19% respectively. Conclusions: Patients with rlaEC were tolerated to neoadjuvant immunotherapy and it might be beneficial to improve efficacy. But this meta-analysis had limitations and the conclusions still needed to be validated by more rigorous phase III randomized controlled clinical trials.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74723479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer and diet: significance of diet in a patient whose life expectancy was 4 to 5 months 癌症与饮食:饮食对预期寿命为4至5个月的患者的意义

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.53388/2023623002

José Ramón Toro López

引用次数: 0

In vivo models of pancreatic ductal adenocarcinoma. 胰腺导管腺癌体内模型。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-03-23 DOI: 10.1016/bs.acr.2023.02.002

Vignesh Vudatha, Kelly M Herremans, Devon C Freudenberger, Christopher Liu, Jose G Trevino

{"title":"In vivo models of pancreatic ductal adenocarcinoma.","authors":"Vignesh Vudatha, Kelly M Herremans, Devon C Freudenberger, Christopher Liu, Jose G Trevino","doi":"10.1016/bs.acr.2023.02.002","DOIUrl":"10.1016/bs.acr.2023.02.002","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with high mortality rate. Within the next decade, PDAC is projected to become the second leading cause of cancer-associated death in the United States. Understanding the pathophysiology of PDAC tumorigenesis and metastases is crucial toward developing new therapeutics. One of the challenges in cancer research is generating in vivo models that closely recapitulate the genomic, histological, and clinical characteristics of human tumors. An ideal model for PDAC not only captures the tumor and stromal environment of human disease, but also allows for mutational control and is easy to reproduce in terms of time and cost. In this review, we highlight evolution of in vivo models for PDAC including spontaneous tumors models (i.e., chemical induction, genetic modification, viral delivery), implantation models including patient derived xenografts (PDX), and humanized PDX. We discuss the implementation of each system and evaluate the benefits and shortcomings of these models. Overall, this review provides a broad overview of prior and current techniques of in vivo PDAC modeling and their associated challenges.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"159 ","pages":"75-112"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10000191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Collaborative Spirit Drives the Field of Tumor Glycobiology: A Preface to Special Volume on Cancer Glycobiology. 协作精神推动肿瘤糖生物学领域：癌症糖生物学特刊序言。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.1016/S0065-230X(23)00010-6

Charles J Dimitroff, Karen L Abbott

引用次数: 0

Setting sail: Maneuvering SHP2 activity and its effects in cancer. 扬帆起航：操纵SHP2活性及其在癌症中的作用。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-04-17 DOI: 10.1016/bs.acr.2023.03.003

Colin L Welsh, Sarah Allen, Lalima K Madan

{"title":"Setting sail: Maneuvering SHP2 activity and its effects in cancer.","authors":"Colin L Welsh, Sarah Allen, Lalima K Madan","doi":"10.1016/bs.acr.2023.03.003","DOIUrl":"10.1016/bs.acr.2023.03.003","url":null,"abstract":"Since the discovery of tyrosine phosphorylation being a critical modulator of cancer signaling, proteins regulating phosphotyrosine levels in cells have fast become targets of therapeutic intervention. The nonreceptor protein tyrosine phosphatase (PTP) coded by the PTPN11 gene \"SHP2\" integrates phosphotyrosine signaling from growth factor receptors into the RAS/RAF/ERK pathway and is centrally positioned in processes regulating cell development and oncogenic transformation. Dysregulation of SHP2 expression or activity is linked to tumorigenesis and developmental defects. Even as a compelling anti-cancer target, SHP2 was considered \"undruggable\" for a long time owing to its conserved catalytic PTP domain that evaded drug development. Recently, SHP2 has risen from the \"undruggable curse\" with the discovery of small molecules that manipulate its intrinsic allostery for effective inhibition. SHP2's unique domain arrangement and conformation(s) allow for a truly novel paradigm of inhibitor development relying on skillful targeting of noncatalytic sites on proteins. In this review we summarize the biological functions, signaling properties, structural attributes, allostery and inhibitors of SHP2.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"160 ","pages":"17-60"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10625904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0